What is Semax and how does it work?
Semax is a synthetic peptide composed of seven amino acids with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP) that acts in the brain through several key mechanisms: it increases the production of proteins that support the growth and survival of brain cells, regulates neurotransmitter balance, controls gene expression, and reduces inflammation – all through interaction with many different receptors on the surface of nerve cells. Amino acids are the building blocks that make up all proteins in the body.
Semax was created by modifying a small, naturally occurring fragment of a hormone called adrenocorticotropic hormone (ACTH) – a hormone released by the body in response to stress – specifically the ACTH(4-10) fragment. Scientists attached a short chain of three amino acids (Pro-Gly-Pro) to it to increase the peptide's resistance to breakdown in the body and prolong its duration of action [1], [2]. Importantly, even though Semax is derived from a stress hormone, it does not behave like a hormone. It does not cause cortisol release or any hormonal side effects, while retaining – and even enhancing – the neuroprotective properties of the original fragment [3]. This unique profile has made Semax one of the most widely studied neuroprotective and cognitive-enhancing peptides, with documented use in stroke treatment and cognitive function support.
Does Semax cross the blood-brain barrier?
Semax effectively crosses the blood-brain barrier after nasal administration, reaching detectable concentrations in brain tissue within minutes. The blood-brain barrier is a highly selective protective layer surrounding the brain's blood vessels, controlling which substances can pass from the blood into brain tissue. Many drugs and compounds cannot cross it.
In studies using a radioactively labeled version of Semax—which allows researchers to track exactly where it goes in the body —rats administered Semax intranasally at a dose of 50 micrograms per kilogram of body weight showed detectable concentrations of the peptide in brain tissue as early as 2 minutes after administration. Approximately 80% of the substance reaching the brain consisted of intact, original Semax molecules, rather than its degradation products [4]. Such rapid delivery is likely made possible by the olfactory pathway—the neural network responsible for the sense of smell—which runs directly from the nasal cavity to the brain, completely bypassing the bloodstream.
Studies have also shown that Semax has a half-life — the time it takes for half of a substance to break down — exceeding one hour in the presence of cell membrane material [5]. This is significantly longer than many naturally occurring brain signaling peptides, confirming Semax's ability to remain active in the brain for a sufficient period to exert significant effects.
Semax acts on NMDA receptors, dopamine receptors, and serotonin receptors.
Semax acts on several different types of receptors in the brain – these are specialized proteins on the surface of cells that act like locks: when the right molecule – the key – binds to the receptor, it triggers a specific reaction inside the cell.
Due to its structural similarity to the ACTH(4-10) fragment, Semax has the ability to interact with melanocortin receptors – a family of receptors involved in various brain and body functions – however, it does so in a non-hormonal and selective manner, without eliciting a full hormonal response [3]. Specialized binding studies – in which researchers used radioactively labeled molecules to track Semax's attachment sites on cell surfaces – identified specific binding sites on the outer membrane of nerve cells in a brain region called the basal forebrain. These sites were found to be calcium-dependent (requiring calcium ions for binding), reversible (Semax can detach from them), and saturable (the number of these sites is finite). The binding affinity (expressed as the dissociation constant, Kd) was approximately 2.4 nM – a value indicating a fairly strong and specific binding – and the total number of binding sites (Bmax) was 33.5 fmol/mg protein [6]. These sites differ from the receptors targeted by classical hormones.
Interestingly, the same studies have shown that two breakdown fragments of Semax – the five-amino-acid peptides HFPGP and EHFPG – exhibited the strongest ability to compete for the same binding sites among all Semax metabolic products. This means that even after the original Semax molecule breaks down, its fragments continue to actively interact with the same receptors, effectively prolonging its duration of action [7].
Semax is also a proposed ligand for the μ-opioid receptor – a receptor more known for its role in pain processing and opioid action – according to computational studies where scientists modeled molecular interactions. Through this receptor, Semax would regulate the protein USP18 and affect the stability of lysosomes – cellular compartments responsible for breaking down and recycling cellular waste [8]. Additional binding studies have shown that Semax also affects the activity of acetylcholine receptors (involved in memory, attention, and muscle control) and GABA receptors (producing calming, inhibitory signals in the brain) in a dose-dependent manner, interacting with both high- and low-affinity GABA binding sites [9].
Direct measurements of the electrical activity of isolated brain cells showed that Semax at a concentration of 1 micromolar increased the electrical currents activated by GABA —inhibitory signals—in cerebellar Purkinje cells by approximately 147%. At the same time, it reduced the currents activated by glycine—another type of inhibitory signal—in hippocampal pyramidal cells (nerve cells in the brain’s memory center) to approximately 43–68% of their normal level [10]. Semax also demonstrated a competitive interaction with metabotropic glutamate receptors—receptors involved in learning, memory, and synaptic plasticity—with an IC50 (the concentration required to produce a 50% inhibitory effect) of approximately 33 micromoles [11].
How does Semax affect BDNF and neurotrophic signaling?
Semax consistently and significantly increases the production of key neurotrophic factors – proteins that the brain produces to keep its cells healthy, support their growth, form new connections, and survive after injury. The two most important of these are brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF).
In studies on rat hippocampal tissue – the hippocampus is the part of the brain most closely associated with learning and memory formation – a single intranasal dose of Semax at 50 micrograms per kilogram of body weight caused a peak 1.4-fold increase in the protein BDNF (meaning BDNF increased to 1.4 times its normal amount). It also caused a 1.6-fold increase in the activation of TrkB – the receptor BDNF binds to, which is how BDNF delivers its effects inside the cell – and a 3-fold and 2-fold increase in genetic instructions (mRNA) for BDNF and TrkB, respectively. mRNA is the molecular message cells use to make proteins; higher levels of mRNA indicate that a cell is actively increasing production. These molecular changes were accompanied by measurable improvements in fear-motivated inhibitory avoidance learning – a standard behavioral test used to assess memory and learning ability in animals [12].
In glial cell cultures—support cells of the brain that maintain the environment for neurons—harvested from the basal forebrain of rats, Semax induced an 8-fold increase in BDNF mRNA and a 5-fold increase in NGF mRNA within just 30 minutes of its administration. This is one of the fastest and most potent neurotrophin-stimulating effects ever reported for a synthetic peptide [13]. These effects also varied by brain region and time: studies tracking BDNF and NGF gene activity at multiple time points after Semax administration revealed significant changes in the hippocampus, frontal cortex, and retina, with an initial transient decrease in hippocampal expression at 20 minutes, followed by a significant increase at 90 minutes and sustained elevated levels in the frontal cortex within an early post-administration window [14].
Importantly, the BDNF-boosting mechanism has also been confirmed in humans. In a clinical trial involving 110 patients recovering from ischemic stroke – a type of stroke caused by a blocked blood vessel cutting off oxygen supply to part of the brain – Semax administration significantly elevated blood BDNF levels regardless of when rehabilitation began, and these elevated levels were sustained throughout the study period. Patients with higher increases in BDNF also showed greater improvement on the Barthel Index – a standard clinical scoring system measuring a person's ability to perform daily activities independently – and a faster return of motor function [15]. This evidence from human studies directly supports the practical significance of the neurotrophic mechanism observed in animal studies.
How does Semax modulate neurotransmitter systems?
Semax affects two key neurotransmitter systems – serotonin and dopamine – but rather than directly increasing or decreasing their levels, it acts more like a fine-tuning mechanism, regulating the activity of these systems. Neurotransmitters are chemical messengers that nerve cells release to communicate with each other across small gaps called synapses.
In the striatum—a brain region involved in motor coordination, reward processing, and habit formation — administration of Semax to rats significantly increased tissue levels of a molecule called 5-hydroxyindoleacetic acid (5-HIAA), which is a byproduct of serotonin breakdown. Higher levels of 5-HIAA indicate increased serotonergic activity. Specifically, tissue levels of 5-HIAA increased by approximately 25% two hours after administration, while levels of 5-HIAA levels measured in the fluid surrounding brain cells gradually rose to approximately 180% of the baseline value over the course of 1–4 hours [16]. This suggests that Semax induces a gradual and sustained increase in serotonergic activity in the striatum.
Regarding dopamine – the neurotransmitter most associated with motivation, reward, and movement – Semax itself did not alter dopamine levels in brain tissue or in the fluid surrounding brain cells under normal resting conditions. However, when administered together with D-amphetamine (a stimulant drug that causes a large release of dopamine), Semax significantly amplified the dopamine-releasing effect caused by the drug, resulting in a markedly higher peak dopamine level in the fluid surrounding brain cells and a more pronounced increase in motor activity compared to amphetamine alone [16], [17]. This pattern, where Semax enhances the dopamine system's response to stimulation without directly triggering dopamine release, suggests it increases the system's sensitivity or readiness, rather than acting as a direct stimulant. This aligns with the observation that Semax does not exhibit addictive potential.
How does Semax work at the level of gene expression?
Semax regulates gene expression in the brain in a way that directly counteracts damage caused by stroke and stress – it reduces the activity of inflammatory genes and restores the activity of genes responsible for proper nerve cell communication. Every cell in the body contains genes – biological instructions telling cells what proteins to produce and when – and gene expression refers to whether a given gene is actively read and used to produce its protein at a given time.
In a rat stroke model – where a blood vessel supplying the brain was temporarily blocked to simulate the type of damage that occurs in humans during a stroke – RNA sequencing analysis (a technique that gives a comprehensive picture of which genes are active or inactive throughout the genome at a given time) identified 394 genes whose activity levels differed in Semax-treated versus untreated animals 24 hours post-stroke. Specifically, Semax reduced the activity of inflammation-driving genes that had been inappropriately turned on by the stroke, while reactivating genes involved in normal brain cell communication that had been inappropriately turned off [18]. More detailed analysis confirmed that Semax significantly reduced the mRNA levels of – and therefore the production instructions for – several key pro-inflammatory proteins: IL-1α, IL-1β, IL-6, CCL3, and CXCL2. These are signaling proteins that, when overproduced, drive harmful inflammation in damaged brain tissue. Semax effectively reversed the stroke-induced increase in their production [19].
Even in healthy rats without brain injury, a single administration of Semax altered the activity of 258 genes in the frontal cortex — an area of the brain responsible for decision-making, attention, and complex thought — with most changes involving a decrease in the activity of genes related to the immune system [20]. This indicates that the gene-regulating effects of Semax are not limited to conditions of injury or disease; they are present even under normal, healthy conditions.
How does Semax work through the synakton mechanism?
Semax does not only work as a single, intact molecule – the term „synakton” describes the concept that Semax functions as part of a coordinated biological system, encompassing both the original peptide and the biologically active fragments into which it breaks down in the body. As enzymes – proteins that break down other molecules – act on Semax in biological tissues, they gradually cleave it into smaller fragments, primarily the five-amino-acid fragment HFPGP, and then the three-amino-acid fragment PGP [5]. Crucially, these fragments are not merely inert byproducts. Each retains its own independent biological activity at overlapping but distinct receptor sites on brain cells [7], meaning the total pharmacological effect of a single dose of Semax extends far beyond the time when the original molecule has already been cleared from the system.
PGP fragment, in particular, has demonstrated the ability to independently activate neurotrophic factors and their receptors after a stroke, stimulate the growth and proliferation of neuroglial cells (support and maintenance cells of the brain) and vascular endothelial progenitor cells (cells that form the inner lining of new blood vessels), as well as regulate the activity of the VEGF gene – a gene controlling the formation of new blood vessels, which is crucial for tissue repair after injury [21], [22]. These independent actions of PGP significantly contribute to the overall neuroprotective and regenerative effects associated with Semax as a whole.
What does Semax do in the body besides the brain?
Semax has documented effects in several organ systems outside of the brain, although most research focuses on its central action. Available evidence indicates significant effects in the cardiovascular, digestive, hepatic, and immune systems.
In the cardiovascular system – the heart and blood vessels – Semax demonstrated antithrombotic (reducing clot formation) and fibrinolytic (promoting the breakdown of existing clots) effects. Nasal administration enhanced the blood's natural antithrombotic properties and its fibrinolytic activity, and reduced the size of experimentally induced clots in animal models [23]. Under stress conditions, such as immobilization stress, Semax also prevented the abnormal increase in blood clotting tendency typically induced by stress and supported the natural anticoagulant system [24].
In the gastrointestinal tract – the stomach and intestines – Semax protected the stomach lining from damage caused by ulcerogenic factors, including alcohol and stress, with protective effects comparable to the action of the PGP fragment itself. It also accelerated the healing of gastric ulcers experimentally induced by acetic acid [25]. At doses of 50 and 150 micrograms per kilogram of body weight, Semax prevented stress-induced disruption of the gut microbiota – the community of beneficial bacteria living in the colon – in chronically stressed rats, maintaining populations of essential bacteria that would otherwise have been significantly reduced by prolonged immobilization stress [26].
In the liver, Semax exerted dose-dependent protective effects on liver cells under both short- and long-term stress conditions, helping to normalize protein synthesis and reduce elevated liver enzymes—blood markers indicative of liver cell damage [27]. In the immune system, Semax acted as an effective immunomodulator—a substance that helps restore normal immune function—in animals subjected to social stress, helping to restore normal cellular immunity, antibody-based immunity, and the activity of neutrophils in fighting infection—a type of white blood cell that attacks pathogens—which had been disrupted by stress [28].
How does Semax interact with the HPA axis?
Semax does not activate the HPA axis nor does it stimulate cortisol release; instead, it works in the opposite direction, dampening the brain's stress response output. The hypothalamic-pituitary-adrenal (HPA) axis is the body's central stress response system, acting like a chain of command: when the brain perceives stress, the hypothalamus signals the pituitary gland (a small gland at the base of the brain), which in turn signals the adrenal glands (small glands on top of the kidneys) to release cortisol, the primary stress hormone.
Although Semax is structurally derived from ACTH—one of the key hormones in this stress signaling cascade—it does not activate the HPA axis and does not stimulate the release of cortisol or corticosterone (the main stress hormone in rodents) [3]. In a chronic unpredictable stress model—an animal research protocol in which rats are exposed to a series of unpredictable stressors over time to simulate the effects of chronic stress—Semax reversed adrenal hypertrophy that typically develops under chronic stress conditions [9]. Adrenal hypertrophy is a widely recognized physical sign of prolonged overactivation of the HPA axis, so its reversal indicates that Semax reduced the overall burden on the stress response system.
The stress-reducing effect was further confirmed by measurements of c-Fos expression—a protein whose presence inside a cell is used as a marker indicating recent activation—in the paraventricular nucleus of the hypothalamus, a specific part of the hypothalamus that initiates the cascade of stress hormones. Semax pretreatment decreased c-Fos expression in this region in stress-susceptible rats, indicating a reduced activation of the hypothalamic stress response to emotional stressors [29]. Collectively, the available evidence suggests that Semax's anti-stress mechanism involves the suppression of the brain's baseline stress signaling, rather than directly interfering with adrenal hormone production.
Disclaimer
This article is for educational and informational-scientific purposes only and should not be interpreted as medical advice, diagnosis, therapeutic recommendation, or a claim regarding the efficacy of Semax in treating any medical condition. Semax remains an investigational compound in most countries, including the United States and most European countries, and is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for treating any medical condition. It is approved and clinically used in Russia and some Eastern European countries. Most of the evidence presented in this article is derived from preclinical animal studies and a limited number of clinical studies in humans, many of which originate from Russian-language scientific literature. Additional well-designed clinical trials are needed to more accurately establish the safety, efficacy, mechanisms of action, and long-term effects of Semax in humans.
References
[1] Ashmarin, I. P., Nezavibat’ko, V. N., Miasoedov, N. F., Kamenskiĭ, A. A., Grivennikov, I. A., Ponomareva-Stepnaia, M. A., Andreeva, L. A., Kaplan, A. Ia., Koshelev, V. B., & Riasina, T. V. (1997). A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study). Journal of Higher Nervous Activity named after I. P. Pavlov, 47(2), 420–430. PMID: 9173745
Natural and hybrid („chimeric”) stable regulatory glyproline peptides. Pathophysiology, 11(4), 179–185. https://doi.org/10.1016/j.pathophys.2004.10.001
Hormonal activity of the ACTH(4-10) analog — a prolonged-action stimulant of learning. Bulletin of Experimental Biology and Medicine, 101(3), 267–268. PMID: 3006824
[4] Shevchenko, K. V., Nagaev, I. Yu., Alfeeva, L. Yu., Andreeva, L. A., Kamenskii, A. A., Levitskaia, N. G., Shevchenko, V. P., Grivennikov, I. A., & Miasoedov, N. F. (2006). Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration. Bioorganic Chemistry, 32(1), 64–70. https://doi.org/10.1134/s1068162006010055
[5] Dolotov, O. V., Zolotarev, Yu. A., Dorokhova, E. M., Andreeva, L. A., Alfeeva, L. Yu., Grivennikov, I. A., & Miasoedov, N. F. (2004). The binding of Semax, ACTH 4-10 heptapeptide, to plasma membranes of the rat forebrain basal nuclei and its biodegradation. Bioorganic Chemistry, 30(3), 241–246. https://doi.org/10.1023/b:rubi.0000030127.46845.f0
[6] Vyunova, T. V., Andreeva, L. A., Shevchenko, K. V., & Myasoedov, N. F. (2017). Synacton and individual activity of synthetic and natural corticotropins. Journal of Molecular Recognition, 30(5). https://doi.org/10.1002/jmr.2597
[7] Vyunova, T. V., Andreeva, L. A., Shevchenko, K. V., Shevchenko, V. P., Bobrov, M. Yu., Bezuglov, V. V., & Myasoedov, N. F. (2014). Characteristic features of specific binding of pentapeptide HFPGP labeled at the C-terminal proline residue to rat forebrain plasma membranes. Doklady Biochemistry and Biophysics, 456(1), 101–103. https://doi.org/10.1134/S1607672914030077
Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. British Journal of Pharmacology, 182(22), 5489–5516. https://doi.org/10.1111/bph.70122
[9] Vyunova, T. V., Andreeva, L. A., Shevchenko, K. V., Glazova, N. Yu., Sebentsova, E. A., Levitskaya, N. G., & Myasoedov, N. F. (2023). Synthetic corticotropins and the GABA-receptor system: Direct and delayed effects. Chemical Biology & Drug Design, 101(6), 1393–1405. https://doi.org/10.1111/cbdd.14221
[10] Sharonova, I. N., Bukanova, Yu. V., Myasoedov, N. F., & Skrebitsky, V. G. (2018). Modulation of GABA- and glycine-activated ionic currents with Semax in isolated cerebral neurons. Bulletin of Experimental Biology and Medicine, 164(5), 612–616. https://doi.org/10.1007/s10517-018-4043-8
[11] Firstova, Yu. Yu., Vasil’eva, E. V., & Kovalev, G. I. (2011). Studying specific effects of nootropic drugs on glutamate receptors in the rat brain. Experimental and Clinical Pharmacology, 74(1), 6–10. PMID: 21476267
[12] Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Yu., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60. https://doi.org/10.1016/j.brainres.2006.07.108
Shadrina, M. I., Dolotov, O. V., Grivennikov, I. A., Slominsky, P. A., Andreeva, L. A., Inozemtseva, L. S., Limborska, S. A., & Myasoedov, N. F. (2001). Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neuroscience Letters, 308(2), 115–118. https://doi.org/10.1016/s0304-3940(01)01994-2
14. Shadrina, M., Kolomin, T., Agapova, T., Agniullin, Y., Shram, S., Slominsky, P., Lymborska, S., & Myasoedov, N. (2010). Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. Journal of Molecular Neuroscience, 41(1), 30–35. https://doi.org/10.1007/s12031-009-9270-z
[15] Gusev, E. I., Martynov, M. Yu., Kostenko, E. V., Petrova, L. V., & Bobyreva, S. N. (2018). The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Journal of Neurology and Psychiatry named after S.S. Korsakov, 118(3), 61–68. https://doi.org/10.17116/jnevro20181183261-68
Eremin, K. O., Kudrin, V. S., Saransaari, P., Oja, S. S., Grivennikov, I. A., Myasoedov, N. F., & Rayevsky, K. S. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
[17] Eremin, K. O., Saransaari, P., Oja, S., & Raevskiĭ, K. S. (2004). Semax potentiates effects of D-amphetamine on the level of extracellular dopamine in the Sprague-Dawley rat striatum and on the locomotor activity of C57BL/6 mice. Experimental and Clinical Pharmacology, 67(2), 8–11. PMID: 15188751
Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Sudarkina, O. Yu., Dmitrieva, V. G., Gubsky, L. V., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2020). Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischaemia-reperfusion in rats. Genes, 11(6), 681. https://doi.org/10.3390/genes11060681
[19] Dergunova, L. V., Dmitrieva, V. G., Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Valieva, L. V., Sudarkina, O. Yu., Gubsky, L. V., Myasoedov, N. F., & Limborska, S. A. (2021). The peptide drug ACTH(4-7)PGP (Semax) suppresses mRNA transcripts encoding proinflammatory mediators induced by reversible ischemia of the rat brain. Molecular Biology, 55(3), 402–411. https://doi.org/10.31857/S0026898421010043
[20] Filippenkov, I. B., Glazova, N. Yu., Sebentsova, E. A., Stavchansky, V. V., Andreeva, L. A., Myasoedov, N. F., Levitskaya, N. G., Limborska, S. A., & Dergunova, L. V. (2024). Changes of transcriptomic activity in rat brain cells under the influence of synthetic adrenocorticotropic hormone-like peptides. Biochemistry (Moscow), 89(9), 1643–1656. https://doi.org/10.1134/S0006297924090104
Dmitrieva, V. G., Povarova, O. V., Skvortsova, V. I., Limborska, S. A., Myasoedov, N. F., & Dergunova, L. V. (2010). Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cellular and Molecular Neurobiology, 30(1), 71–79. https://doi.org/10.1007/s10571-009-9432-0
[22] Stavchansky, V. V., Yuzhakov, V. V., Botsina, A. Yu., Skvortsova, V. I., Bondurko, L. N., Tsyganova, M. G., Limborska, S. A., Myasoedov, N. F., & Dergunova, L. V. (2011). The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: A pilot study. Journal of Molecular Neuroscience, 45(2), 177–185. https://doi.org/10.1007/s12031-010-9421-2
[23] Cherkasova, K. A., Lyapina, L. A., & Ashmarin, I. P. (2001). Comparative study of modulatory effects of Semax and primary proline-containing peptides on hemostatic reactions. Bulletin of Experimental Biology and Medicine, 132(1), 625–626. https://doi.org/10.1023/a:1012503606536
[24] Grigorjeva, M. E., & Lyapina, L. A. (2010). Anticoagulation and antiplatelet effects of semax under conditions of acute and chronic immobilization stress. Bulletin of Experimental Biology and Medicine, 149(1), 44–46. https://doi.org/10.1007/s10517-010-0871-x
[25] Zhuikova, S. E., Smirnova, E. A., Bakaeva, Z. V., Samonina, G. E., & Ashmarin, I. P. (2000). Effect of Semax on homeostasis of gastric mucosa in albino rats. Bulletin of Experimental Biology and Medicine, 130(9), 871–873. PMID: 11177268
[26] Svishcheva, M. V., Mukhina, A. Yu., Medvedeva, O. A., Shevchenko, A. V., Bobyntsev, I. I., Kalutskii, P. V., Andreeva, L. A., & Myasoedov, N. F. (2020). Composition of colon microbiota in rats treated with ACTH(4-7)-PGP peptide (Semax) under conditions of restraint stress. Bulletin of Experimental Biology and Medicine, 169(3), 357–360. https://doi.org/10.1007/s10517-020-04886-7
Bobyntsev, I. I., Shepeleva, O. M., Kryukov, A. A., Ivanov, A. V., & Belykh, A. E. (2015). The effect of peptide ACTH4-7-PGP on functional hepatocyte state in rats in acute and chronic foot-shock stress. Sechenov Physiological Journal of Russia(2), 171–179. PMID: 26012109
[28] Samotrueva, M. A., Yasenyavskaya, A. L., Murtalieva, V. Kh., Bashkina, O. A., Myasoedov, N. F., Andreeva, L. A., & Karaulov, A. V. (2019). Experimental substantiation of the application of Semax as a modulator of immune response in a „social” stress model. Bulletin of Experimental Biology and Medicine, 166(6), 754–758. https://doi.org/10.1007/s10517-019-04434-y
[29] Umriukhin, P. E., Koplik, E. V., Grivennikov, I. A., Miasoedov, N. F., & Sudakov, K. V. (2001). Gene c-Fos expression in the brain of rats resistant and predisposed to emotional stress after intraperitoneal injection of the ACTH(4-10) analog — Semax. Journal of Higher Nervous Activity named after I. P. Pavlov, 51(2), 220–227. PMID: 11548604